Amrin (NASDAQ: AMRN ) The pharmaceutical company is in a particularly precarious position. This fact is highlighted by the company’s recent move to restructure its operations in an effort to cut costs. And Vascepa, a drug it has to sell, already faces generic competition in the United States. Most investors would be fine with a large pharmaceutical company.
Perhaps the most positive thing about Amerin is its balance sheet. The company has no long-term debt, a cash balance of approximately $135 million, and short-term investments worth just under $168 million. In short, it is in a very strong financial position and is likely to continue its business for years to come.
Will AI create the world’s first trillionaire? Our team just published a report on a little-known company, called “Essential Dependency” that provides critical technology to both Nvidia and Intel. Continue »
Meanwhile, despite Vascapa’s exposure to the US market, it is a revenue-generating product. By 2025, Amerin had product sales of approximately $183 million. And restructuring efforts in 2025 have helped the company cut costs. Management believes the restructuring will help generate positive free cash flow in 2026. A pharmaceutical company with no debt and positive free cash flow will usually be hard to complain about.
For the most part, the good news ends there. The big risk is that the company’s sales two years ago were $285 million. So there has been a shortage of material on the top line. The fact that its only drug faced generic competition in the US market has a lot to do with declining revenue. With no other products to rely on, Amerin has little choice but to recoup costs or face a quick deterioration of its strong financial position.
Essentially, the company does this by trying to milk every dollar from the only drugs it sells. But it does not operate from a position of operational power. The biggest risk is that as the company’s revenue continues to decline, the company will simply reduce its business in order to protect itself. This is unlikely to produce good results for the stakeholders.
To be fair, the drug cycle that Amrin is dealing with is completely normal in the pharma sector. The problem is that the company only has one drug to sell. If it was a large company with a broad portfolio of drugs, it would have a strong foundation to work from. If you’re willing to take the risk associated with Amarin, you’re probably better off buying a preferred drug from a pharmaceutical manufacturer. Pfizer (NYSE: PFE ) on the spot.
